Humacyte, Inc. (HUMA)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.24 per share a year ago.
Humacyte Q2 Earnings Call Highlights
Humacyte NASDAQ: HUMA reported second-quarter commercial sales growth while outlining plans to expand adoption of its SYMVESS vascular repair product, submit a supplemental biologics license application for dialysis access and begin a first-in-human coronary bypass study.
Humacyte, Inc. (HUMA) Rises As Market Takes a Dip: Key Facts
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.73, signifying a +2.33% move from its prior day's close.
Humacyte, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Nelson Arrington V. M. MANNING & CO. Inc. | 31,609 | $24,668 | $20,640.68 | -$4,027.32 | -16.33% |
 Curtis Ellergodt Rothschild Investment LLC | 1,090 | $661 | $773.46 | $112.46 | 17.01% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 13,330 | $10,400 | $9,570.94 | -$829.06 | -7.97% |
| IH Isaac Haas Hbk Investments LP | 790,000 | $616,516 | $477,791.99 | -$138,724.01 | -22.5% |
| AB Anthony Bruccoleri Equitable Holdings Inc. | 20,000 | $30,000 | $12,100 | -$17,900 | -59.67% |
Humacyte, Inc. (HUMA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Humacyte, Inc. ever had a stock split?
Humacyte, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Laura E. Niklason CEO | NASDAQ (NGS) Exchange | 44486Q103 CUSIP |
| US Country | 184 Employees | - Last Dividend | - Last Split | 24 Nov 2020 IPO Date |
Overview
Humacyte, Inc. is a pioneering healthcare company that specializes in the development and manufacturing of innovative bioengineered human tissues designed for the treatment of various diseases and conditions. The company’s focus is on creating implantable, off-the-shelf tissues that can be used in a wide range of therapeutic areas and anatomic locations. Founded in 2004 and based in Durham, North Carolina, Humacyte leverages its proprietary scientific technology platform to engineer human acellular vessels (HAVs) that, when implanted into patients, are intended not to induce a foreign body response or lead to immune rejection. This technology represents a significant step forward in vascular repair, reconstruction, and replacement, aiming to revolutionize the field of regenerative medicine and improve patient outcomes across multiple treatment areas.
Products and Services
- Vascular Trauma Repair:
- Arteriovenous Access for Hemodialysis:
- Peripheral Arterial Disease (PAD):
- Pediatric Heart Surgery:
- Coronary Artery Bypass Grafting:
- Delivery of Cellular Therapies:
Humacyte is developing HAVs to address the critical need for durable, readily available vascular grafts in the treatment of traumatic injuries. These bioengineered vessels are designed to restore blood flow and facilitate the healing process in patients who have suffered from severe vascular damage.
The company’s HAVs offer a promising solution for patients requiring hemodialysis access. These vessels aim to provide a more reliable and longer-lasting alternative to current arteriovenous fistulas and grafts, potentially reducing complications and improving the quality of life for patients with end-stage renal disease.
For patients suffering from PAD, Humacyte’s HAVs are being developed to improve blood circulation to the limbs. This innovative approach could offer a significant advancement over traditional treatments, potentially avoiding amputations and enhancing patient mobility and comfort.
In the realm of congenital heart disease, Humacyte’s HAVs are investigated as potential solutions to pediatric heart defects. These bioengineered tissues could provide a revolutionary new option for the repair or reconstruction of pediatric vascular structures, offering hope for improved outcomes in young patients.
Humacyte is exploring the use of HAVs in coronary artery bypass grafting, a common procedure to improve blood flow to the heart. The company aims to provide surgeons with a superior alternative to traditional graft materials, potentially reducing the risk of complications and enhancing patient recovery.
Additionally, Humacyte’s technology platform is being utilized for the delivery of cellular therapies, including the transplantation of pancreatic islet cells to treat Type 1 diabetes. This innovative application of HAVs could offer a novel approach to cellular delivery, aiming to improve therapeutic efficacy and patient outcomes.
